Welcome to our dedicated page for Apogee Therapeutics news (Ticker: APGE), a resource for investors and traders seeking the latest updates and insights on Apogee Therapeutics stock.
Apogee Therapeutics, Inc. (Nasdaq: APGE) is a clinical-stage biotechnology company developing engineered biologic therapies for inflammatory and immunology (I&I) diseases, and its news flow reflects the progress and risks typical of this sector. Company announcements frequently highlight clinical trial updates for its lead IL‑13 antibody APG777 (zumilokibart) in atopic dermatitis and asthma, as well as data from earlier-stage programs such as APG279, APG333 and APG990.
Investors following APGE news can expect detailed reports on Phase 1 and Phase 2 study results, including safety, pharmacokinetics, biomarker responses and efficacy endpoints in conditions like moderate-to-severe atopic dermatitis and mild-to-moderate asthma. Recent releases have described 16-week data from the APEX Phase 2 trial in atopic dermatitis, interim Phase 1b data in asthma showing durable FeNO suppression, and first-in-human results for APG333 in healthy volunteers, all of which the company uses to frame its development strategy and dosing hypotheses.
Apogee’s news feed also covers corporate and financial milestones, such as quarterly financial results, public equity offerings under an effective shelf registration statement, and participation in healthcare and immunology conferences. These items provide context on the company’s cash runway, research and development spending, and planned timelines for future clinical readouts and potential Phase 3 trial initiations.
For readers tracking APGE, the news page offers a centralized view of regulatory filings referenced in press releases, scientific conference presentations, and management commentary on pipeline priorities. Regular updates on APG777, APG279, APG333 and related programs help investors, analysts and observers monitor how Apogee’s I&I pipeline is advancing through the clinic and how new data may influence its development plans.
Apogee Therapeutics (Nasdaq: APGE) has announced its upcoming participation in the Guggenheim SMID Cap Biotech Conference. The company's management team will engage in a fireside chat scheduled for Wednesday, February 5, 2025, at 1:00 p.m. E.T. Interested parties can access both live and archived versions of the presentation through the News & Events page in the Investors section of the Apogee Therapeutics website.
Apogee Therapeutics (APGE) has initiated dosing in its Phase 1 clinical trial of APG333, a novel subcutaneous half-life extended monoclonal antibody targeting TSLP for respiratory and inflammatory conditions. The trial marks the company's fourth clinical program in under 18 months.
The Phase 1 trial is designed as a double-blind, placebo-controlled study in healthy volunteers, evaluating safety, tolerability, and pharmacokinetics. The study will enroll approximately 32 healthy adults across 4 cohorts, with interim data expected in second half of 2025.
The company plans to explore APG333 initially for asthma treatment, with potential combination therapy with APG777. Preclinical studies of the APG777 + APG333 combination have shown promising results in inhibiting inflammation with potential for less frequent dosing.
Apogee Therapeutics (APGE) shared positive updates during its 2024 R&D Day, highlighting progress across its inflammatory and immunology pipeline. APG808 showed positive Phase 1 data with a 55-day half-life, supporting 2-3 month dosing potential. APG777 demonstrated promising 12-month data with a 77-day half-life, suggesting possible annual dosing. The company accelerated its APG777 Phase 2 Part A trial topline data to mid-2025.
The company achieved preclinical proof-of-concept for both APG777 + APG990 and APG777 + APG333 combinations for various conditions including atopic dermatitis, asthma, and COPD. A Phase 1b head-to-head trial against DUPIXENT is planned for 2025 with data expected in 2H 2026.
Apogee Therapeutics (Nasdaq: APGE) announced the agenda for its upcoming virtual R&D Day scheduled for December 2, 2024. The event will feature presentations from key opinion leaders including Dr. Emma Guttman-Yassky and Dr. David Singh, alongside the company's management team. The agenda includes discussions on APG808 Phase 1 clinical trial interim results, APG777 updates, and strategies for addressing atopic dermatitis, asthma, and COPD treatments. The presentations will focus on the company's approach to inflammatory and immunology conditions, particularly through IL-13 and combination therapies.
Apogee Therapeutics (Nasdaq: APGE) has announced its inaugural virtual R&D Day, scheduled for December 2, 2024, at 10:00 a.m. ET. The event will showcase the company's progress in developing novel biologics for inflammatory and immunology (I&I) conditions, including atopic dermatitis, asthma, and chronic obstructive pulmonary disease.
The presentation will feature management updates focusing on APG777's potential in atopic dermatitis treatment, combination therapy strategies, and commercial opportunities in I&I markets. Key opinion leaders will discuss the current treatment landscape and emerging opportunities for patients with these conditions.
Apogee Therapeutics (APGE) reported Q3 2024 financial results and pipeline updates. The company highlighted positive 9-month results from APG777's Phase 1 trial, supporting its potential best-in-class profile with a 75-day half-life. Key financial metrics include $753.8M in cash providing runway into 2028, R&D expenses of $45.7M, and a net loss of $49.0M. The company is advancing multiple clinical programs, including APG777 (Phase 2 data expected 2H 2025), APG808 (Phase 1 interim data in Q4 2024), and APG990 (Phase 1 interim data in 1H 2025). Additionally, APG333 was selected as a development candidate with Phase 1 initiation planned for late 2024 or early 2025.
Apogee Therapeutics (APGE), a clinical-stage biotech company focused on inflammatory and immunology treatments, announces its participation in three major investor conferences this November. The company will present at the Guggenheim Inaugural Healthcare Innovation Conference on November 12 at 3:00 p.m. ET, the Stifel 2024 Healthcare Conference on November 18 at 10:20 a.m. ET, and the Jefferies London Healthcare Conference on November 20 at 10:30 a.m. ET. Live and archived webcasts will be accessible through Apogee's website investor section.
Apogee Therapeutics (APGE) announced updated positive results from its Phase 1 trial of APG777, a novel anti-IL-13 antibody for atopic dermatitis treatment. The trial demonstrated a well-tolerated safety profile with doses up to 1,200mg, showing a half-life of approximately 75 days - three to five times longer than current treatments. Key findings include dose-proportional pharmacokinetics, near-complete inhibition of pSTAT6, and sustained TARC inhibition up to 9 months. The company expects to report Phase 2 proof-of-concept data in 2H 2025, with potential for maintenance dosing every 3-6 months compared to current biweekly or monthly treatments.
Apogee Therapeutics (Nasdaq: APGE) has announced an upcoming poster presentation at the American College of Allergy, Asthma & Immunology's (ACAAI) 2024 Annual Scientific Meeting in Boston from October 24-28, 2024. The presentation will showcase data up to 9 months from the ongoing Phase 1 clinical trial of APG777, a novel half-life extended anti-IL-13 antibody for treating atopic dermatitis and other inflammatory diseases.
The poster, titled "APG777, anti-IL-13 monoclonal antibody, demonstrates extended half-life and sustained inhibition of Type 2 inflammatory biomarkers," will be presented on Friday, October 25, from 2:00-6:00 p.m. ET at the Hynes Convention Center. The presentation will be available on Apogee's website on October 24.
Apogee Therapeutics (Nasdaq: APGE), a clinical-stage biotechnology company, has announced its participation in the Stifel 2024 Immunology and Inflammation Summit. The company's management will engage in a fireside chat on September 18, 2024, at 12:30 p.m. E.T. / 9:30 a.m. P.T.
Apogee specializes in developing novel biologics for major inflammatory and immunology (I&I) markets, focusing on treatments for atopic dermatitis, asthma, chronic obstructive pulmonary disease (COPD), and other I&I indications. Their approach aims to offer potentially differentiated efficacy and dosing options.
Interested parties can access a live and archived webcast of the presentation through the News & Events page in the Investors section of Apogee Therapeutics' website.